Quick Win by the Algorithm: Geron Corporation (NASDAQ: GERN) Treats Investors With Stock Up 24.71% In 3 Days

Quick Algorithm

“With the preliminary data from IMerge presented at ASH, we now have clinical data in three blood cancers, ET, MF and MDS, where imetelstat exhibits potential disease modifying activity by inhibiting the progenitor cells of the malignant clones that drive the underlying diseases”

– said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer.

(Image Source: www.troutaccess.com)

Geron Corporation (NASDAQ: GERN) operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the

Read More